ArticleCancer medicine2025
Blue Light Emitting Diode Suppresses Sarcoma Cell Proliferation via the Endogenous Apoptotic Pathway Without Damaging Normal Cells.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intraperitoneal blue LED irradiation as a potential approach to suppress gastric cancer peritoneal dissemination in a murine model.Scientific reports · 2026Article
- Label-Free Detection of HeLa Cells Activity Excited by Blue LED.Sensors (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe development of novel therapies for sarcoma is urgently required because most sarcomas are refractory to adjuvant therapy and the treatment options are limited. Although antitumor effects of blue light (BL) have been reported for several malignant tumors, its impact on various sarcomas remains unknown. In this study, we examined the antitumor effects of BL on several kinds of bone and soft tissue sarcomas.
methodsWe used human osteosarcoma, undifferentiated pleomorphic sarcoma, liposarcoma, and myxofibrosarcoma cell lines, as well as a human dermal fibroblast cell line as normal cells. We continuously irradiated these cells with BL in an incubator.
resultsBL inhibited cell proliferation in sarcoma cells, but hardly affected normal cells. BL increased intracellular reactive oxygen species (ROS) levels in sarcoma cells, but not in normal cells. Interestingly, oxidative stress occurred after BL irradiation in both sarcoma and normal cells. In addition, apoptosis, autophagy, and mitochondrial dysfunction, which were induced by ROS, occurred in sarcoma cells. In undifferentiated pleomorphic sarcoma cells, BL caused cell death through activation of the endogenous apoptotic pathway, and autophagy counteracted the apoptosis.
conclusionOur results indicate that BL might specifically kill sarcoma cells without injuring normal cells and may become a new treatment option for sarcoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.